TELA Bio Inc. Common Stock (TELA)
Stock · NASDAQ · Health Care
$0.9685as of 10/16/2026
Price chart
Active signals
TELA Signal Track Record
How signals performed across all stocks →What TELA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 44 | -2.4% | 43% | September 16, 2026 |
| Bollinger Band Breakdown | 27 | -4.7% | 41% | June 24, 2026 |
| Bollinger Band Breakout | 14 | +1.2% | 57% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -5.4% | 33% | August 10, 2026 |
| Any 20-session window (baseline) | -4.2% | 36% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TELA
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to a…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 218
- Website
- www.telabio.com/
Fundamentals
- 1-day range
- $0.9677$1.11
- Market cap
- $38.50M
- P/E (trailing)
- —
- P/E (forward)
- -2.17
- EPS (trailing)
- $-0.77
- Dividend yield
- —
- Beta
- 1.42
- Avg. volume
- 222.0K
How TELA Bio Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
TELA Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TELATELA Bio Inc. Common Stock$0.975▼ 3.47%Market cap $38.50MP/E —$0.5011$1.56
- NEPHNephros Inc. Common Stock$3.65▲ 3.99%Market cap $38.98MP/E 21.52$2.66$6.42
- PAVMPAVmed Inc. Common Stock$2.41▼ 0.62%Market cap $35.93MP/E —$2.27$28.44
- NSPRInspireMD Inc. Common Stock$0.46▼ 4.17%Market cap $33.87MP/E —$0.4604$2.54
- ARAYAccuray Incorporated Common Stock$0.16▼ 5.88%Market cap $33.63MP/E —$0.1615$1.86
- BEATHeartbeam Inc. Common Stock$0.436▲ 0.93%Market cap $28.33MP/E —$0.355$4
- SRTSSensus Healthcare Inc. Common Stock$2.77▲ 0.00%Market cap $49.06MP/E —$2.66$5.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TELA TELA Bio Inc. Common Stock | $38.50M | — | $0.975 | ▼ 3.47% | $0.5011$1.56 |
| NEPH Nephros Inc. Common Stock | $38.98M | 21.52 | $3.65 | ▲ 3.99% | $2.66$6.42 |
| PAVM PAVmed Inc. Common Stock | $35.93M | — | $2.41 | ▼ 0.62% | $2.27$28.44 |
| NSPR InspireMD Inc. Common Stock | $33.87M | — | $0.46 | ▼ 4.17% | $0.4604$2.54 |
| ARAY Accuray Incorporated Common Stock | $33.63M | — | $0.16 | ▼ 5.88% | $0.1615$1.86 |
| BEAT Heartbeam Inc. Common Stock | $28.33M | — | $0.436 | ▲ 0.93% | $0.355$4 |
| SRTS Sensus Healthcare Inc. Common Stock | $49.06M | — | $2.77 | ▲ 0.00% | $2.66$5.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- TELA Bio, Inc. (TELA) Shareholder/Analyst Call TranscriptSeekingAlpha · 10/8/2026
- TELA Bio Says FDA Cleared Liora Resorbable Surgical Mesh For Soft Tissue Reinforcementbenzinga · 10/5/2026
- TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue ReinforcementYahoo · 10/5/2026
- 5 Stock Picks Last Week From Wall Street's Most Accurate AnalystsBenzinga · 9/28/2026
- Craig-Hallum Initiates Coverage On TELA Bio with Buy Rating, Announces Price Target of $2Benzinga · 9/25/2026
Insider Activity
Insider Actions →- Joseph H. Capper · September 17, 2026 · Buy25.0K @ $1.22
- Joseph H. Capper · September 16, 2026 · Buy50.0K @ $1.17
- Joseph H. Capper · September 15, 2026 · Buy50.0K @ $1.06
- Joseph H. Capper · September 14, 2026 · Buy25.0K @ $1.02
- Heather C. Getz · August 17, 2026 · Buy12.5K @ $0.6649
- Heather C. Getz · August 14, 2026 · Buy15.0K @ $0.6978
- Heather C. Getz · August 3, 2026 · Grant1.00M
- Heather C. Getz · August 3, 2026 · Grant1.36M
- Heather C. Getz · August 3, 2026 · Grant500.0K
- William J. Plovanic · July 15, 2026 · Grant20.9K @ $0.785
- Joseph H. Capper · July 15, 2026 · Grant6.2K @ $0.785
- Guy P. Nohra · June 9, 2026 · Grant11.9K
- Paul Thomas · June 9, 2026 · Grant17.3K
- Paul Thomas · June 9, 2026 · Grant17.6K
- Paul Thomas · June 9, 2026 · Grant11.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 27.41M
- Total value held
- $17.03M
- Institutional holders
- 33
- Unknown7.71M
- Unknown5.89M
- Unknown2.62M
- Unknown2.26M
- Unknown1.54M
- Unknown1.44M
- Unknown1.42M
- Unknown1.06M
- Unknown750.0K
- Unknown636.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Craig-Hallum initiates coverage on TELA Bio with $2 target
Craig-Hallum has started tracking TELA Bio, assigning a price target of $2. This new analyst note aligns with the current average analyst target of $2.08. The stock is currently trading above its 52-week low of $0.50, with recent technical indicators showing momentum near the upper end of its recent range.
Craig-Hallum initiates coverage on TELA Bio with $2 target. Craig-Hallum has started tracking TELA Bio, assigning a price target of $2. This new analyst note aligns with the current average analyst target of $2.08. The stock is currently trading above its 52-week low of $0.50, with recent technical indicators showing momentum near the upper end of its recent range.